Ipilimumab vs Metformin
Ipilimumab vs Metformin: Overview
This comparison examines the pharmacological differences between Ipilimumab and Metformin.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Metformin: Activates AMP-activated protein kinase, decreasing hepatic glucose production.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days; Metformin — 4-9 hours.
Chemical Properties
Molecular Formula: Metformin — C4H11N5.
Molecular Weight: Metformin — 129.1640 g/mol.
Type: Ipilimumab — Antibody; Metformin — Small molecule.